Illinois clinic one of first places in the country to offer new device to spinal cord injury patients
Callahan has a spinal cord injury, so he wasn't supporting all of his own weight or moving his legs by himself. But something had changed. He had a little bit of sensation in his feet.
'It's pretty strange,' said Callahan, 22, of Lockport, who was injured as a passenger in a car accident 1 1/2 years ago. Since he started using the device with the electrodes, he said, he can feel his feet touching surfaces, though they still can't feel pain or temperature. 'I think there's definitely noticeable progress.'
The device, called the ARC-EX, delivers electrical pulses to his spine during his sessions at Next Steps Chicago, a neurological rehabilitation clinic in Willow Springs. The device was approved by the U.S. Food and Drug Administration in December, with some experts hailing it as a milestone in therapy for people with spinal cord injuries. Next Steps is one of the first two clinics in the country offering it.
'It's pretty miraculous,' said Mary Jones, a physical therapist and director of operations at Next Steps Chicago. 'I spent my career working toward this and to see it come to fruition is nothing short of amazing.'
Now, during Callahan's appointments at Next Steps, neuro-adaptive exercise specialist Creighton Goss attaches electrodes to the back of Callahan's neck along his cervical spine and then midway down his back, near his thoracic spine. Thin electrical cables connect the electrodes to the ARC-EX device, which delivers continuous electrical pulses throughout Callahan's appointment.
The stimulation doesn't hurt, but 'It definitely wakes you up,' Callahan said with a smile.
The ARC-EX is not the first device to deliver electrical stimulation through the skin to help people with spinal cord injuries. But unlike other commercially available devices, the ARC-EX delivers stimulation directly to the spine, rather than to other parts of the body that a person wishes to move, such as to an arm or a leg. The idea is to restore hand strength and sensation even when stimulation is no longer used.
The device is supposed to be used for up to an hour a day, alongside therapy or training, to help improve hand strength and sensation for people with incomplete spinal cord injuries. About two-thirds of people with spinal cord injuries in the U.S. have incomplete injuries, meaning that though their movement may be extremely limited, their spinal cords have not completely lost the ability to transmit messages to and from the brain.
'Some instruction from the brain gets through but not enough to create a movement, so we're providing an amplification of that signal from the brain,' said Dave Marver, CEO of Onward Medical, the company that sells the device.
Dr. Arun Jayaraman, executive director of the Technology & Innovation Hub at Chicago rehabilitation hospital Shirley Ryan AbilityLab, who is not involved with Next Steps, called the device 'an additional tool' that can be used to improve spinal cord signals to the limbs. He said it's the first device of its kind to be FDA-approved and available for everyday use by clinicians, rather than just for research purposes. The AbilityLab has an agreement to use the device for its research studies in stroke and other medical conditions later this year.
The device's FDA approval is 'huge' for the spinal cord injury community, said Marco Baptista, chief scientific officer with the Christopher and Dana Reeve Foundation, which helped support the device's development with an investment in Onward. Philanthropic venture fund SCI Ventures, which was co-founded by the foundation and other nonprofits, now holds that investment, and any revenue received from the investment will go toward supporting more research, Baptista said.
'One, this can be a device that can help people, and, two, it provides this path forward that other therapies can then follow,' Baptista said.
Next Steps Chicago, a standalone nonprofit, helped test an earlier version of the device and has always felt it's important to bring cutting-edge technologies into the community, Jones said.
'This is a catastrophic lifelong condition,' Jones said of spinal cord injuries. 'To make somebody's life a little bit easier, to give them 10% improvement, that's a big deal for someone who hasn't moved their arm or is dependent on someone else for round-the-clock care.'
The device costs clinics about $40,000, Marver said — not a small price tag, but also not the most expensive piece of equipment a clinic like Next Steps uses.
In a study funded by Onward and published in May in the peer-reviewed journal Nature Medicine, 72% of participants saw improved strength and function in their hands and arms after using the device. The FDA specifically approved the device to be used to improve hand sensation and strength.
Improving hand function is a priority for many people with spinal cord injuries, Marver said, sometimes even more so than regaining the ability to walk.
'They need their hands to get through activities of daily living, to feed themselves, to clothe themselves, to go to the bathroom,' Marver said. 'These are all things that introduce independence, dignity, quality of life.'
The device doesn't work for everyone, but so far Next Steps has seen about a dozen patients have positive results, including Callahan, Jones said. Though Callahan still has hand function, the device has helped with other areas of his body, Jones said.
Callahan said he'd been a patient at Next Steps for about a year when Jones asked him if he wanted to try the ARC-EX device.
'She was explaining the research behind it and the possible benefits of using it, and it seemed it was applicable to my injury, so I thought why not,' Callahan said.
Callahan uses a wheelchair and is paralyzed from the diaphragm down. After his accident, he spent about two months as an inpatient at AbilityLab and then another six months doing outpatient rehab with the AbilityLab.
Now, he goes to Next Steps about three times a week, for two hours at a time, where he practices movement in the treatment gym. At a recent appointment, Goss had him kneel in front of a low table, which he used to brace himself, using his arms. Goss then slowly helped Callahan move his legs back and forth, an exercise designed to help him practice shifting weight from one leg to the other.
Callahan isn't sure how much strength, movement or sensation he'll ever regain. Everyone and every injury is different. 'Nothing is guaranteed,' Callahan said, but he's trying to recover as much as he can.
'It would definitely improve my quality of life, not just for me, but for my family,' Callahan said of the prospect of regaining more function.
'We're hoping you walk in one day and say, 'Peace out, I'm done,'' Goss said. 'That would be the goal.'
'That would be the goal,' Callahan agreed.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

14 hours ago
Rich's Ice Cream products recalled due to possible listeria contamination
The recall was firm initiated on June 27. 0:46 Ice cream fans should check their freezers following a voluntary recall of 10 Rich's Ice Cream Co. products that were sold across 23 states. According to a report from the U.S. Food and Drug Administration on July 17 that assigned the recall a Class II designation, the West Palm Beach-based ice cream maker initiated the recall voluntarily due to potential Listeria monocytogenes contamination. The Class II designation indicates that use of the recalled product could cause "temporary or medically reversible adverse health consequences," with a remote probability of serious adverse health consequences, according to the FDA. As of time of publication, the company has not said if there have been any reported illnesses tied to this recall. Rich's Ice Cream Co. did not immediately respond to ABC News' request for comment. Details of Rich's Ice Cream recall Ten products total have been impacted by this recall, according to the FDA report, including certain lots of the brand's Chocolate Crunch Cake Bar ice cream, as well as some lots of its Strawberry Shortcake Bars, Rich Bars, Crumbled Cookie Bars, Orange Cream Bars, Fudge Frenzy Bars, Cotton Candy Twirl Bars, Savagely Sour BlueRasberry Bars, Savagely Sour Cherry Bars and Cool Watermelon Bars. The recall covers the above products with lot code numbers 24351 through 25156, according to the FDA. Click here for full details, including packaging and product descriptions. The affected products were distributed across 23 states including California, Pennsylvania, Ohio, Georgia, New York, New Jersey, Florida, Texas, Virginia, Arizona, Alabama, Illinois, Missouri, Massachusetts, Tennessee, Iowa, South Carolina, Oregon, Oklahoma, Nevada, Louisiana, Wisconsin and Nebraska, as well as Nassau, Bahamas. What to know about listeria and its symptoms Listeria is a bacteria that when ingested can cause an infection known as listeriosis, according to the Centers for Disease Control and Prevention. The condition is most dangerous for pregnant people, newborns, people with weakened immune systems and adults 65 or older, the agency says. For people who are pregnant, being infected by listeria can cause pregnancy loss or premature birth. According to the CDC, an estimated 1,600 people get listeriosis annually in the U.S. and about 260 people die from it.
Yahoo
21 hours ago
- Yahoo
Tempus Receives U.S. FDA 510(k) Clearance for Tempus ECG-Low EF Software
CHICAGO, July 16, 2025--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Tempus ECG-Low EF (ejection fraction) software, which uses AI to identify certain patients who may have a low left ventricular ejection fraction (LVEF). Tempus ECG-Low EF joins Tempus ECG-AF as the second FDA-cleared ECG-AI device in Tempus' growing suite of next generation devices designed to identify patients at risk for a variety of cardiovascular conditions. "With Tempus ECG-Low EF, we're adding another powerful tool to the hands of clinicians to help them identify patients at risk for serious cardiovascular conditions much earlier in their care journey," said Brandon Fornwalt, MD, PhD, Senior Vice President of Cardiology at Tempus. "Detection of LVEF is essential for undiagnosed patients, and this technology enables us to deliver that capability at scale to transform patient care. The addition of a second FDA-cleared Tempus ECG-AI solution reflects our continued commitment to advancing AI-driven cardiology." Ejection fraction measures the percentage of blood that the heart pumps out with each beat. A reduced LVEF may indicate a range of serious cardiovascular conditions, including heart failure, cardiomyopathy, or damage from a prior heart attack. Tempus ECG-Low EF is software intended to analyze resting, non-ambulatory 12-lead ECG recordings and detect signs associated with having a low left ventricular ejection fraction (LVEF less than or equal to 40%). It is for use on clinical diagnostic ECG recordings collected at a healthcare facility from patients 40 years of age or older at risk of heart failure. This population includes but is not limited to patients with atrial fibrillation, aortic stenosis, cardiomyopathy, myocardial infarction, diabetes, hypertension, mitral regurgitation, and ischemic heart disease. Tempus ECG-Low EF only analyzes ECG data and provides a binary output for interpretation. Tempus ECG-Low EF is not intended to be a stand-alone diagnostic tool for cardiac conditions, should not be used for patient monitoring, and should not be used on ECGs with paced rhythms. Results should be interpreted in conjunction with other diagnostic information, including the patient's original ECG recordings and other tests, as well as the patient's symptoms and clinical history. A positive result may suggest the need for further clinical evaluation in order to establish a diagnosis of low LVEF. Patients receiving a negative result should continue to be evaluated in accordance with current medical practice standards using all available clinical information. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit Forward Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus' industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the expected outcomes and benefits of Tempus ECG-Low EF and its capabilities for customers. In some cases, you can identify forward-looking statements because they contain words such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "going to," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release. You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus' business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: Tempus' financial performance; the ability to attract and retain customers and partners; managing Tempus' growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus' intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" in Tempus' Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC") on February 24, 2025, as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law. View source version on Contacts Hanah Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data


Business Insider
a day ago
- Business Insider
Why Is ProMIS Neurosciences Stock (PMN) Up 180% Today?
ProMIS Neurosciences (PMN) stock surged on Monday after the precision medicine solutions company was granted Fast Track designation for PMN310 by the U.S. Food and Drug Administration (FDA). This is a therapeutic candidate in development at the company to treat Alzheimer's disease. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. ProMIS Neurosciences noted that PMN310 is currently undergoing a Phase 1b trial evaluating its safety, tolerability, pharmacokinetics, and disease-relevant biomarkers in patients with early Alzheimer's disease. The company expects interim results from this trial in Q2 2026 and final results in Q4 2026. PMN stock was up 177.21% in pre-market trading on Monday, following a 6.38% drop on Friday. The stock has also decreased 53.67% year-to-date and 77.2% over the past 12 months. With today's rally came heavy trading, with more than 79 million shares traded, compared to a three-month daily average of about 3.5 million shares. Is ProMIS Neurosciences Stock a Buy, Sell, or Hold? Turning to Wall Street, the analysts' consensus rating for ProMIS Neurosciences is Moderate Buy, based on two Buy ratings over the past three months. With that comes an average PMN stock price target of $3.50, representing a potential 695.27% upside for the shares.